U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H22N2S.ClH.H2O
Molecular Weight 364.933
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PECAZINE HYDROCHLORIDE MONOHYDRATE

SMILES

O.Cl.CN1CCCC(CN2C3=CC=CC=C3SC4=CC=CC=C24)C1

InChI

InChIKey=TWEHDGPVRLPOEF-UHFFFAOYSA-N
InChI=1S/C19H22N2S.ClH.H2O/c1-20-12-6-7-15(13-20)14-21-16-8-2-4-10-18(16)22-19-11-5-3-9-17(19)21;;/h2-5,8-11,15H,6-7,12-14H2,1H3;1H;1H2

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C19H22N2S
Molecular Weight 310.456
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

PECAZINE is a phenothiazine derivative that was used as an antipsychotic. It is also an allosteric inhibitor of MALT1 paracaspase activity.

CNS Activity

Approval Year

1957
118
Doses

Doses

DosePopulationAdverse events​
75 mg 3 times / day multiple, oral
Recommended
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
unhealthy, 20-59
Health Status: unhealthy
Age Group: 20-59
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Disc. AE: Agranulocytosis...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis (3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
unhealthy, 35
Health Status: unhealthy
Age Group: 35
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
Disc. AE: Agranulocytosis...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
300 mg multiple, oral
Recommended
Dose: 300 mg
Route: oral
Route: multiple
Dose: 300 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
unhealthy, 37.1±1.5
Health Status: unhealthy
Age Group: 37.1±1.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Disc. AE: Cycloplegia...
AEs leading to
discontinuation/dose reduction:
Cycloplegia (4%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
900 mg multiple, oral
Highest studied dose
Dose: 900 mg
Route: oral
Route: multiple
Dose: 900 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
25 mg 3 times / day multiple, oral
Studied dose
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Disc. AE: Jaundice...
AEs leading to
discontinuation/dose reduction:
Jaundice
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
AEs

AEs

AESignificanceDosePopulation
Agranulocytosis 3%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
unhealthy, 20-59
Health Status: unhealthy
Age Group: 20-59
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Agranulocytosis Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
unhealthy, 35
Health Status: unhealthy
Age Group: 35
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
Cycloplegia 4%
Disc. AE
300 mg multiple, oral
Recommended
Dose: 300 mg
Route: oral
Route: multiple
Dose: 300 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
unhealthy, 37.1±1.5
Health Status: unhealthy
Age Group: 37.1±1.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Jaundice Disc. AE
25 mg 3 times / day multiple, oral
Studied dose
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY562589
https://www.001chemical.com/chem/60-89-9
Alfa Chemistry
60-89-9
https://www.alfa-chemistry.com/cas_60-89-9.htm
Aurora Fine Chemicals LLC
K02.237.593
http://online.aurorafinechemicals.com/info?ID=K02.237.593
Chem Scene
CS-0081367
http://www.chemscene.com/60-89-9.html
Chemspace
CSSS00102561680
https://chem-space.com/CSSS00102561680
eNovation Chemicals
D931422
https://www.enovationchem.com/ProductDetails.asp?ProductID=D931422
Lab Network
LN01302729
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01302729
Matrix Scientific
176622
https://www.matrixscientific.com/176622.html
mcule
MCULE-4399173403
https://mcule.com/MCULE-4399173403/
MedChem Express
HY-121282
https://www.medchemexpress.com/mepazine.html
Molcore
MC562589
https://www.molcore.com/product/60-89-9
Smolecule
S538872
http://www.smolecule.com/products/s538872
THE BioTek
bt-278398
https://www.thebiotek.com/product/inhibitors/bt-278398
VladaChem
VL130984
https://www.vladachem.com/product.php?products=60-89-9
Yuhao Chemical
SY0043
http://www.chemyuhao.com/60-89-9.html
PubMed

PubMed

TitleDatePubMed
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011-07-14
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.
2010-03-03
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:22:37 GMT 2025
Edited
by admin
on Mon Mar 31 18:22:37 GMT 2025
Record UNII
AF6V3D768R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEPAZINE HYDROCHLORIDE MONOHYDRATE
MI  
Preferred Name English
PECAZINE HYDROCHLORIDE MONOHYDRATE
Common Name English
(±)-MEPAZINE HYDROCHLORIDE MONOHYDRATE
Common Name English
MEPAZINE HYDROCHLORIDE MONOHYDRATE [MI]
Common Name English
MEPAZINE HYDROCHLORIDE MONOHYDRATE, (±)-
Common Name English
10H-PHENOTHIAZINE, 10-((1-METHYL-3-PIPERIDINYL)METHYL)-, MONOHYDROCHLORIDE, MONOHYDRATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66883
Created by admin on Mon Mar 31 18:22:37 GMT 2025 , Edited by admin on Mon Mar 31 18:22:37 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID80977024
Created by admin on Mon Mar 31 18:22:37 GMT 2025 , Edited by admin on Mon Mar 31 18:22:37 GMT 2025
PRIMARY
FDA UNII
AF6V3D768R
Created by admin on Mon Mar 31 18:22:37 GMT 2025 , Edited by admin on Mon Mar 31 18:22:37 GMT 2025
PRIMARY
NCI_THESAURUS
C80675
Created by admin on Mon Mar 31 18:22:37 GMT 2025 , Edited by admin on Mon Mar 31 18:22:37 GMT 2025
PRIMARY
PUBCHEM
44154839
Created by admin on Mon Mar 31 18:22:37 GMT 2025 , Edited by admin on Mon Mar 31 18:22:37 GMT 2025
PRIMARY
CAS
6146-88-9
Created by admin on Mon Mar 31 18:22:37 GMT 2025 , Edited by admin on Mon Mar 31 18:22:37 GMT 2025
PRIMARY
MERCK INDEX
m816
Created by admin on Mon Mar 31 18:22:37 GMT 2025 , Edited by admin on Mon Mar 31 18:22:37 GMT 2025
PRIMARY Merck Index
Related Record Type Details
Structure of PECAZINE
PARENT -> SALT/SOLVATE
Structure of PECAZINE HYDROCHLORIDE
ANHYDROUS->SOLVATE
Related Record Type Details
Structure of PECAZINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966